| abstract |
a bifunctional fusion protein targeting cd47 and pd-l1, which belongs to the field of biomedicine and solves the problems that anti-pd-1 / pd-l1 treatment has little effect on low immunogenic tumors and anti-cd47 treatment has bad targeting properties. the fusion protein consists of a fraction of binding to cd47 and a fraction of binding to pd-l1 bound by means of a disulfide bond, it can block both the binding of cd47 to sirpa and the binding of pd-l1 to pd-1, not only activating phagocytosis of tumor cell macrophages and promoting the presentation of antigens in innate immunity, but also promoting the activation of tumor-specific t cells in acquired immunity, and has less hematological toxicity. the fusion protein has better anti-tumor efficacy and hematological safety than anti-pd-l1 or anti-cd47 therapy alone, and animals from which a tumor has disappeared after treatment of the fusion protein produce immunity against reinoculation of the same tumor cell . |